Sensei Biotherapeutics Initiated at Overweight by Stephens & Co.
Sensei Biotherapeutics Initiated at Overweight by Stephens & Co.
Sensei Biotherapeutics (SNSE.US) was covered for the first time by Stephens & Co. with an increase rating, with a target price of $5.00.
Sensei Biotherapeutics (SNSE.US) was covered for the first time by Stephens & Co. with an increase rating, with a target price of $5.00.
Stephens & Co. Initiates Coverage On Sensei Biotherapeutics With Overweight Rating, Announces Price Target of $5
Stephens & Co. analyst Sudan Loganathan initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Overweight rating and announces Price Target of $5.
Sensei Biotherapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 195.86% Stephens & Co. → $5 Initiates Coverage On → Overweight 12/04/2023 136.69% HC Wainwright
Buy Rating Justified for Sensei Biotherapeutics Amidst Strong Pipeline and Financial Stability
Sensei Biotherapeutics Poised for Growth: A Strong Buy Rating Amid Financial Stability and Promising Clinical Trials
Sensei Biotherapeutics | 10-Q: Quarterly report
Sensei Biotherapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.
Sensei Biotherapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 GAAP EPS Results.
Sensei Biotherapeutics Q1 2024 GAAP EPS $(0.32) Misses $(0.29) Estimate
Sensei Biotherapeutics Q1 2024 GAAP EPS $(0.32) Misses $(0.29) Estimate
Sensei Biotherapeutics 1Q Loss $7.99M >SNSE
Sensei Biotherapeutics 1Q Loss $7.99M >SNSE
Sensei Biotherapeutics: Strong Balance Sheet With Cash Runway Into 4Q of 2025 >SNSE
Sensei Biotherapeutics: Strong Balance Sheet With Cash Runway Into 4Q of 2025 >SNSE
Sensei Biotherapeutics: Cash, Cash Equivalents and Marketable Securities Were $58.1 M as of March 31 >SNSE
Sensei Biotherapeutics: Cash, Cash Equivalents and Marketable Securities Were $58.1 M as of March 31 >SNSE
Press Release: Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limitin
JAGX, SNSE and BON Among Mid-day Movers
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out
Sensei Biotherapeutics to Present Topline Clinical Data From the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeut
12 Health Care Stocks Moving In Monday's After-Market Session
GainersNuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. The company's market cap stands at $3.2 million. Sensei Biotherapeutics (NASDAQ:SNSE) stock rose 7.42% to
Sensei Biotherapeutics Extends Relationship With Former CFO
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA Within the Tumor Microenvironment
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced the publication of a peer-reviewed research paper in Nature Communications.
No Data